Kannadit Prayongratana
Overview
Explore the profile of Kannadit Prayongratana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tirachotikul T, Rattanathammethee T, Makruasi N, Chintabanyat A, Julamanee J, Khuhapinant A, et al.
Ann Hematol
. 2024 Aug;
103(12):5741-5748.
PMID: 39177795
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of T-cell lymphomas with a characteristic feature of subcutaneous nodules associated with hemophagocytic lymphohistiocytosis (HLH). Treatment options for SPTCL are mainly...
2.
Thanhakun R, Wudhikarn K, Bunworasate U, Rattanathammethee T, Norasetthada L, Kanya P, et al.
Ann Hematol
. 2023 Sep;
102(12):3533-3541.
PMID: 37718327
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which...
3.
Rattanathammethee T, Norasetthada L, Bunworasate U, Wudhikarn K, Julamanee J, Noiperm P, et al.
Ann Hematol
. 2023 May;
102(7):1887-1895.
PMID: 37202499
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate...
4.
Kungwankiattichai S, Owattanapanich W, Rattanathammethee T, Rattarittamrong E, Chanswangphuwana C, Polprasert C, et al.
Hematology
. 2023 Mar;
28(1):2191462.
PMID: 36951362
Introduction: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with a unique clinical presentation and prognosis. This study aimed to investigate the epidemiology, clinical characteristics,...
5.
Apipongrat D, Roytrakul S, Prayongratana K, Charoenpitakchai M, Intharanut K, Laoruangroj C, et al.
PLoS One
. 2022 Dec;
17(12):e0278464.
PMID: 36454786
Multiple myeloma (MM) is an incurable plasma cell malignancy accounting for approximately 10% of hematological malignancies. Identification of reliable biomarkers for better diagnosis and prognosis remains a major challenge. This...
6.
Chanswangphuwana C, Polprasert C, Owattanapanich W, Kungwankiattichai S, Tantiworawit A, Rattanathammethee T, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Sep;
22(12):e1075-e1083.
PMID: 36117042
Background: Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) both result in dismal outcomes. This retrospective study aimed to determine whether these features are poor prognostic factors...
7.
Chanswangphuwana C, Polprasert C, Owattanapanich W, Kungwankiattichai S, Rattarittamrong E, Rattanathammethee T, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jul;
22(10):e915-e921.
PMID: 35792033
Background: Intermediate or high doses of cytarabine (IDAC or HiDAC) were recommended as postremission chemotherapy for acute myeloid leukemia (AML). This retrospective study investigated the real-world outcomes of 3-different cytarabine...
8.
Wanitpongpun C, Utchariyaprasit E, Owattanapanich W, Tantiworawit A, Rattarittamrong E, Niparuck P, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Apr;
21(7):e635-e643.
PMID: 33926829
Background: Acute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of...
9.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2614-2621.
PMID: 32573294
Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage...
10.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Hematol Oncol
. 2019 Nov;
37(5):578-585.
PMID: 31702065
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T...